Eli Lilly has pledged an additional US$3 billion investment in China over the next decade to strengthen its local supply chain and manufacturing capabilities, deepening the footprint of foreign pharmaceutical giants in the world’s second-largest healthcare market.
The move would bring the total cumulative investment of Eli Lilly, the world’s largest pharmaceutical company by market capitalisation, in China to nearly US$6 billion, according to a statement released on its WeChat account on…
Eli Lilly boosts China footprint with US$3 billion plan to expand supply chain
